Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Gerber

Showing results (171-180 of 190) with videos related to

Pageof 19
Sort By:
NPJ Precision Oncology|December 27, 2022
Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORMHeike Peterziel, Nora Jamaladdin, Dina ElHarouni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2025
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II TrialJuliet C Gray, Rebekah Weston, Cormac Owens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2020
Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation CohortMartin Mynarek, Katja von Hoff, Torsten Pietsch, et al.
Nature Medicine|March 12, 2024
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Nature Medicine|November 18, 2023
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Nature Medicine|April 16, 2025
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Cancer Discovery|April 21, 2021
Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion-Positive Supratentorial EpendymomasTuyu Zheng, David R Ghasemi, Konstantin Okonechnikov, et al.
Neuro-Oncology|September 30, 2025
Developing an advanced risk stratification model for pediatric intracranial ependymoma based on the prospective trial E-HIT2000 and subsequent registriesKatja von Hoff, Denise Obrecht-Sturm, David R Ghasemi, et al.
Neuro-Oncology|April 5, 2025
Salvage therapies for first relapse of SHH medulloblastoma in early childhoodCraig Erker, Martin Mynarek, Marie Simbozel, et al.
Nature Medicine|October 24, 2023
Author Correction: Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncologyDominik Sturm, David Capper, Felipe Andreiuolo, et al.
Pageof 19

Showing results (171-180 of 190) with videos related to

Sort By:
Pageof 19
NPJ Precision Oncology|December 27, 2022
Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORMHeike Peterziel, Nora Jamaladdin, Dina ElHarouni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2025
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II TrialJuliet C Gray, Rebekah Weston, Cormac Owens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2020
Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation CohortMartin Mynarek, Katja von Hoff, Torsten Pietsch, et al.
Nature Medicine|March 12, 2024
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Nature Medicine|November 18, 2023
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Nature Medicine|April 16, 2025
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialLindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, et al.
Cancer Discovery|April 21, 2021
Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion-Positive Supratentorial EpendymomasTuyu Zheng, David R Ghasemi, Konstantin Okonechnikov, et al.
Neuro-Oncology|September 30, 2025
Developing an advanced risk stratification model for pediatric intracranial ependymoma based on the prospective trial E-HIT2000 and subsequent registriesKatja von Hoff, Denise Obrecht-Sturm, David R Ghasemi, et al.
Neuro-Oncology|April 5, 2025
Salvage therapies for first relapse of SHH medulloblastoma in early childhoodCraig Erker, Martin Mynarek, Marie Simbozel, et al.
Nature Medicine|October 24, 2023
Author Correction: Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncologyDominik Sturm, David Capper, Felipe Andreiuolo, et al.
Pageof 19